Glioblastoma therapy: Going beyond Hercules columns

Expert Review of Neurotherapeutics

Volumn 10, Issue 4, 2010, Pages 507-514

  Mangiola, Annunziato ^a   Anile, Carmelo ^a   Pompucci, Angelo ^a   Capone, Gennaro ^a   Rigante, Luigi ^a   De Bonis, Pasquale ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

brain adjacent to tumor; EGF receptor; glioblastoma; immunotherapy; peritumor area; temozolomide; therapy; VEGF

Indexed keywords

BEVACIZUMAB; CANCER VACCINE; CARMUSTINE; CEDIRANIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FAS LIGAND; GADOLINIUM TEXAPHYRIN; GEFITINIB; HYDROXYUREA; IMATINIB; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 8; MAMMALIAN TARGET OF RAPAMYCIN; PICIBANIL; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE B; TEMOZOLOMIDE; TEMSIROLIMUS; VASCULOTROPIN; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLOOD BRAIN BARRIER; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CELL INFILTRATION; DENDRITIC CELL; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; GENE MUTATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GLIOBLASTOMA; GLIOMA; HUMAN; MULTIPLE CYCLE TREATMENT; NATURAL KILLER CELL; NEWCASTLE DISEASE PARAMYXOVIRUS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT FAILURE; TUMOR LOCALIZATION; BRAIN TUMOR; GENETICS; MULTIMODALITY CANCER THERAPY; NEUROSURGERY; PATHOLOGY; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; GLIOBLASTOMA; HUMANS; NEUROSURGICAL PROCEDURES; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77953642472     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.09.158     Document Type: Review

References (59)

1. Furnari FB, Fenton T, Bachoo RM et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 21, 2683-2710 (2007).
2. Parsons DW, Jones S, Zhang X et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321(5897), 1807-1812 (2008).
3. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455(7216), 1061-1068 (2008).
4. Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 62(4), 753-764 (2008).
5. Simpson JR, Horton J, Scott C et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int. J. Radiat. Oncol. Biol. Phys. 26, 239-244 (1993).
6. Brandes AA, Tosoni A, Franceschi e et al. Glioblastoma in adults. Crit. Rev. Oncol. Hematol. 67(2), 139-152 (2008).
7. Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N. Engl. J. Med. 356, 1527-1535 (2007).
8. Ford JM, Seiferheld W, Alger JR et al. Results of the Phase I dose-escalating study of motexafin gadolinium with standard radiotherapy in patients with glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys. 69, 831-838 (2007).
9. Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352, 997-1003 (2005).
10. Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised Phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10(5), 459-466 (2009).
11. Lefranc F, Facchini V, Kiss R. Pro-autophagic drugs: a novel means to combat apoptosis-resistant cancers. Oncologist 12, 1395-1403 (2007).
12. Mathieu V, De Nève N, Le Mercier M et al. Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model. Neoplasia 10(12), 1383-1392 (2008).
13. Brandes AA, Tosoni A, Basso U et al. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a Phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J. Clin. Oncol. 22, 4779-4786 (2004).
14. Franceschi E, Omuro AM, Lassman AB, Demopoulos A, Nolan C, Abrey LE. Salvage temozolomide for prior temozolomide responders. Cancer 104, 2473-2476 (2005).
15. Mellinghoff IK, Wang MY, Vivanco I et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 353, 2012-2024 (2005).
16. Haas-Kogan DA, Prados MD, Tihan T et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J. Natl Cancer Inst. 97, 880-887 (2005).
17. Lassman AB, Rossi MR, Razier JR et al. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium trials 01-03 and 00-01. Clin. Cancer Res. 11, 7841-7850 (2005).
18. Rich JN, Reardon DA, Peery T et al. Phase II trial of gefitinib in recurrent glioblastoma. J. Clin. Oncol. 22(1), 133-142 (2004).
19. van den Bent MJ, Brandes AA, Rampling R et al. Randomized Phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J. Clin. Oncol. 27(8), 1268-1274 (2009).
20. Vredenburgh JJ, Desjardins A, Herndon JE II et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol. 25, 4722-4729 (2007).
21. Batchelor TT, Sorensen AG, di Tomaso E et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11, 83-95 (2007).
22. Chang SM, Wen P, Cloughesy T et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest. New Drugs 23, 357-361 (2005).
23. Galanis E, Buckner JC, Maurer MJ et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J. Clin. Oncol. 23(23), 5294-5304 (2005).
24. Guha A, Dashner K, Black PM, Wagner JA, Stiles CD. Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop. Int. J. Cancer 60, 168-173 (1995).
25. George D. Platelet-derived growth factor receptors: a therapeutic target in solid tumors. Semin. Oncol. 28 (Suppl. 17), 27-33 (2001).
26. Raymond E, Brandes A, Van Osterom A et al. Multicenter Phase II study of imatinib mesylate in patients with recurrent glioblastoma: an EORTC NCCG/BTG Intergroup study. 2004 ASCO Annual Meeting Proceedings. J. Clin. Oncol. 22 (14 S), 1501(2004).
27. van den Bent M, Brandes A, Frenay M et al. Multicenter Phase II study of imatinib mesylate in patients with recurrent anaplastic oligodendroglioma (AOD)/mixed oligoastrocytoma (MOA) and anaplastic astrocytoma (AA)/low-grade astrocytoma (LGA): an EORTC New Drug Development Group (NDDG) and Brain Tumor Group (BTG) study. 2005 ASCO Annual Meeting Proceedings. J. Clin. Oncol. 23 (16 S), 1517(2005).
28. Raymond E, Campone M, Stupp R et al. Multicenter Phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiforme. Eur. J. Cancer 38, 1348-1350 (2002).
29. Dresemann G. Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. Ann. Oncol. 16, 1702-1708 (2005).
30. Westphal M, Hilt DC, Bortey e et al. A Phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 5, 79-88 (2003).
31. Olivi A, Grossman SA, Tatter S et al. Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS Consortium trial. J. Clin. Oncol. 21(9), 1845-1849 (2003).
32. Galli R, Binda E, Orfanelli U et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 64, 7011-7021 (2004).
33. Singh SK, Clarke ID, Hide T, Dirks PB. Cancer stem cells in nervous system tumors. Oncogene 23, 7267-7273 (2004).
34. Salmaggi A, Boiardi A, Gelati M et al. Glioblastoma-derived tumorospheres identify a population of tumor stem-like cells with angiogenic potential and enhanced multidrug resistance phenotype. Glia 54(8), 850-860 (2006).
35. Ishikawa E, Tsuboi K, Saijo K et al. Autologous natural killer cell therapy for human recurrent malignant glioma. Anticancer Res. 24, 1861-1871 (2004).
36. Yajima N, Yamanaka R, Mine T et al. Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin. Cancer Res. 11, 5900-5911 (2005).
37. Caruso DA, Orme LM, Neale AM et al. Results of a Phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer. Neuro Oncol. 6, 236-246 (2004).
38. Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T cells in patients with malignant glioma. Cancer Res. 64, 4973-4979 (2004).
39. Rutkowski S, De Vleeschouwer S, Kaempgen e et al. Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma: a feasibility study. Br. J. Cancer 91, 1656-1662 (2004).
40. Yamanaka R, Homma J, Yajima N et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical Phase I/II trial. Clin. Cancer Res. 11(11), 4160-4167 (2005).
41. Badie B, Schartner J, Prabakaran S, Paul J, Vorpahl J. Expression of fas ligand by microglia: possible role in glioma immune evasion. J. Neuroimmunol. 120, 19-24 (2001).
42. Morandi E, Zingaretti C, Chiozzotto D et al. A cDNA-microarray analysis of camptothecin resistance in glioblastoma cell lines. Cancer Lett. 231, 74-86 (2006).
43. Yu JS, Luptrawan A, Black KL, Liu G. Mahaley clinical research award: chemosensitization of glioma through dendritic cell vaccination. Clin. Neurosurg. 53, 345-351 (2006).
44. Liu G, Akasaki Y, Khong HT et al. Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy. Oncogene 24, 5226-5234 (2005).
45. Parney IF, Chang LJ, Farr-Jones MA, Hao C, Smylie M, Petruk KC. Technical hurdles in a pilot clinical trial of combined B7-2 and GM-CSF immunogene therapy for glioblastomas and melanomas. J. Neurooncol. 78, 71-80 (2006).
46. Steiner HH, Bonsanto MM, Beckhove P et al. Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit. J. Clin. Oncol. 22(21), 4272-4281 (2004).
47. Burger PC, Dubois PJ, Schold SC Jr et al. Computerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiforme. J. Neurosurg. 58, 159-169 (1983).
48. Silbergeld DL, Chicoine MR. Isolation and characterization of human malignant glioma cells from histologically normal brain. J. Neurosurg. 86, 525-531 (1997).
49. Schiffer D, Cavalla P, Dutto A, Borsotti L. Cell proliferation and invasion in malignant glioma. Anticancer Res. 17, 61-69 (1997).
50. Dalrymple SJ, Parisi JE, Roche PC, Ziesmer SC, Scheithauer BW, Kelly PJ. Changes in proliferating cell nuclear antigen expression in glioblastoma multiforme cells along a stereotactic biopsy trajectory. Neurosurgery 35, 1036-1044 (1994).
51. Berens ME, Giese A. "...those left behind." Biology and oncology of invasive glioma cells. Neoplasia 1, 208-219 (1999).
52. Lefranc F, Brotchi J, Kiss R. Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J. Clin. Oncol. 23(10), 2411-2422 (2005).
53. Mangiola A, de Bonis P, Maira G et al. Invasive tumor cells and prognosis in a selected population of patients with glioblastoma multiforme. Cancer 113(4), 841-846 (2008).
54. Lama G, Mangiola A, Anile C et al. Activated ERK1/2 expression in glioblastoma multiforme and in peritumor tissue. Int. J. Oncol. 30(6), 1333-1342 (2007).
55. Mangiola A, Lama G, Giannitelli C et al. Stem cell marker nestin and c-Jun. NH2-terminal kinases in tumor and peritumor areas of glioblastoma multiforme: possible prognostic implications. Clin. Cancer Res. 13(23), 6970-6977 (2007).
56. Erratum in: Clin. Cancer Res. 14(15), 4995-4996 (2008).
57. Piccirillo SG, Combi R, Cajola L et al. Distinct pools of cancer stem-like cells coexist within human glioblastomas and display different tumorigenicity and independent genomic evolution. Oncogene 28(15), 1807-1811 (2009).
58. le Sage C, Nagel R, Egan DA et al. Regulation of the p27 (Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J. 26(15), 3699-3708 (2007).
59. Ciafre SA, Galardi S, Mangiola A et al. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem. Biophys. Res. Commun. 334, 1351-1358 (2005).